In this series, three presenters discuss the importance of early screening and the need for a multidisciplinary approach to identify patients at risk for CKD. Watch the presentations and answer the questions in the tests!
The CANVAS biomarker substudy showed that canagliflozin delays the expected increase in CV biomarkers in T2DM patients. It also reduces the risk of HF and renal disease events irrespective of biomarker levels at baseline.
Three speakers present the KDIGO guidelines, evidence of studies with GLP-1RAs and kidney outcomes and tell us what we can expect in the near future with regard to GLP-1RAs in nephrology.
"We really need to think about a collaborative, integrated approach, where primary care and specialists are working together to manage CKD", says Prof. Khunti.
Watch a discussion by three experts on the importance of early screening and the need for a multidisciplinary approach to identify patients at risk for CKD.
Watch a discussion by three experts on the role of GLP-1RA in preventing CKD in patients with diabetes.
Rikke Borg gives an overview on CKD in patients with diabetes with a focus on how to screen for early signs of CKD.
At the beginning of empagliflozin treatment, a mild eGFR decrease is to be expected. However, this does not deprive patients with HFrEF from benefiting from SGLT2i therapy, according to a secondary analysis of the EMPEROR-Reduced trial.
Prof. Wanner gives an introduction on improving early identification of CKD and changing the eGFR slope of patients with diabetes by working together with other healthcare professionals.
The American Diabetes Association (ADA) has made important updates to the Standard of Medical Care in Diabetes 2022. Updates include new data on finerenone in T2DM and CKD, SGLT2i in T2DM and calculating eGFR.
In this video, Prof. Tuttle discusses GLP-1RAs for CVD risk reduction and preservation of kidney function in CKD. Moreover, she talks about multidisciplinary team care for patients with T2DM and CKD.
GLP-1RAs may result in beneficial effects on renal outcomes, as shown by analyses of secondary endpoints in large trials. What are the potential mechanisms leading to CVD and CKD risk reduction?